Last reviewed · How we verify

NCT04170387: Fibrorilax

Can a Relaxometer Improve Cognitive Impairment of Fibromyalgia Patients

Status unknown NA Last updated 16 December 2019
What this trial tests

NA trial testing Relaxometer in Fibromyalgia Syndrome in 40 participants. Status unknown.

Timeline
15 December 2019
Primary endpoint
15 December 2019
14 October 2020

Quick facts

Lead sponsorAzienda Ospedaliera Universitaria Integrata Verona
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationnon randomized
Designparallel
Maskingnone
Primary purposesupportive care
Enrollment40
Start date15 December 2019
Primary completion15 December 2019
Estimated completion14 October 2020

Drugs / interventions tested

Conditions studied

Sponsor

Azienda Ospedaliera Universitaria Integrata Verona — full company profile →

Who can join

Adults 18 to 65, any sex, with Fibromyalgia Syndrome or Fibromyalgia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of the study is to evaluate the differences in cognitive performance and quality of life, after a cycle of treatment with the relaxometer, between a group of patients affected by fibromyalgia and a control group.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Fibromyalgia Syndrome

Currently open trials in the same condition.

Other Azienda Ospedaliera Universitaria Integrata Verona trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04170387.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing